Cargando…
Peri-operative chemotherapy for resectable colorectal lung metastasis: a systematic review and meta-analysis
PURPOSE: Several studies have evaluated surgical resection of pulmonary metastases as a standard treatment option for colorectal cancer (CRC) patients with resectable pulmonary metastases. However, the role of peri-operative chemotherapy after complete resection of pulmonary metastases from CRC pati...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039839/ https://www.ncbi.nlm.nih.gov/pubmed/32036456 http://dx.doi.org/10.1007/s00432-020-03142-9 |
_version_ | 1783500862150148096 |
---|---|
author | Li, Yuting Qin, You |
author_facet | Li, Yuting Qin, You |
author_sort | Li, Yuting |
collection | PubMed |
description | PURPOSE: Several studies have evaluated surgical resection of pulmonary metastases as a standard treatment option for colorectal cancer (CRC) patients with resectable pulmonary metastases. However, the role of peri-operative chemotherapy after complete resection of pulmonary metastases from CRC patients is still controversial. This systematic review and meta-analysis is aimed to investigate the clinical efficacy of peri-operative chemotherapy after resection of CRC pulmonary metastases. METHODS: PubMed, the Cochrane Library databases, and Embase were searched for studies evaluating the effect of peri-operative chemotherapy on the survival of patients with CRC after pulmonary metastasectomy. The hazard ratio (HR) was used for analyzing overall survival (OS) and progression-free survival (PFS)/recurrence-free survival (RFS)/disease-free survival (DFS). RESULTS: Eight studies were included in the final analysis. The outcome showed that peri-operative chemotherapy had a significant favourable effect on OS (HR 0.83, 95% CI 0.75–0.92, p < 0.05) and PFS/RFS/DFS (HR 0.67, 95% CI 0.53–0.86, p < 0.05) in patients who received pulmonary metastasectomy. Multivariate analysis also validated this result (OS: HR 0.56, 95% CI 0.36–0.86, p < 0.05; PFS/RFS/DFS: HR 0.64, 95% CI 0.46–0.87, p < 0.05). There was a significant benefit in peri-operative group on OS and PFS/RFS/DFS in studies with R0 resection of pulmonary metastases (OS: HR 0.72, 95% CI 0.53–0.97, p < 0.05; PFS/RFS/DFS: HR 0.72, 95% CI 0.54–0.95, p < 0.05) and metachronous pulmonary metastases (OS: HR 0.40, 95% CI 0.22–0.75, p < 0.05; PFS/RFS/DFS: HR 0.67, 95% CI 0.49–0.92, p < 0.05). CONCLUSION: Our meta-analysis demonstrated a significant difference in favor of peri-operative chemotherapy in CRC patients who underwent resection of pulmonary metastases. More clinical data and studies are needed to validate the findings of our study. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00432-020-03142-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7039839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-70398392020-03-09 Peri-operative chemotherapy for resectable colorectal lung metastasis: a systematic review and meta-analysis Li, Yuting Qin, You J Cancer Res Clin Oncol Review – Cancer Research PURPOSE: Several studies have evaluated surgical resection of pulmonary metastases as a standard treatment option for colorectal cancer (CRC) patients with resectable pulmonary metastases. However, the role of peri-operative chemotherapy after complete resection of pulmonary metastases from CRC patients is still controversial. This systematic review and meta-analysis is aimed to investigate the clinical efficacy of peri-operative chemotherapy after resection of CRC pulmonary metastases. METHODS: PubMed, the Cochrane Library databases, and Embase were searched for studies evaluating the effect of peri-operative chemotherapy on the survival of patients with CRC after pulmonary metastasectomy. The hazard ratio (HR) was used for analyzing overall survival (OS) and progression-free survival (PFS)/recurrence-free survival (RFS)/disease-free survival (DFS). RESULTS: Eight studies were included in the final analysis. The outcome showed that peri-operative chemotherapy had a significant favourable effect on OS (HR 0.83, 95% CI 0.75–0.92, p < 0.05) and PFS/RFS/DFS (HR 0.67, 95% CI 0.53–0.86, p < 0.05) in patients who received pulmonary metastasectomy. Multivariate analysis also validated this result (OS: HR 0.56, 95% CI 0.36–0.86, p < 0.05; PFS/RFS/DFS: HR 0.64, 95% CI 0.46–0.87, p < 0.05). There was a significant benefit in peri-operative group on OS and PFS/RFS/DFS in studies with R0 resection of pulmonary metastases (OS: HR 0.72, 95% CI 0.53–0.97, p < 0.05; PFS/RFS/DFS: HR 0.72, 95% CI 0.54–0.95, p < 0.05) and metachronous pulmonary metastases (OS: HR 0.40, 95% CI 0.22–0.75, p < 0.05; PFS/RFS/DFS: HR 0.67, 95% CI 0.49–0.92, p < 0.05). CONCLUSION: Our meta-analysis demonstrated a significant difference in favor of peri-operative chemotherapy in CRC patients who underwent resection of pulmonary metastases. More clinical data and studies are needed to validate the findings of our study. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00432-020-03142-9) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-02-08 2020 /pmc/articles/PMC7039839/ /pubmed/32036456 http://dx.doi.org/10.1007/s00432-020-03142-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review – Cancer Research Li, Yuting Qin, You Peri-operative chemotherapy for resectable colorectal lung metastasis: a systematic review and meta-analysis |
title | Peri-operative chemotherapy for resectable colorectal lung metastasis: a systematic review and meta-analysis |
title_full | Peri-operative chemotherapy for resectable colorectal lung metastasis: a systematic review and meta-analysis |
title_fullStr | Peri-operative chemotherapy for resectable colorectal lung metastasis: a systematic review and meta-analysis |
title_full_unstemmed | Peri-operative chemotherapy for resectable colorectal lung metastasis: a systematic review and meta-analysis |
title_short | Peri-operative chemotherapy for resectable colorectal lung metastasis: a systematic review and meta-analysis |
title_sort | peri-operative chemotherapy for resectable colorectal lung metastasis: a systematic review and meta-analysis |
topic | Review – Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039839/ https://www.ncbi.nlm.nih.gov/pubmed/32036456 http://dx.doi.org/10.1007/s00432-020-03142-9 |
work_keys_str_mv | AT liyuting perioperativechemotherapyforresectablecolorectallungmetastasisasystematicreviewandmetaanalysis AT qinyou perioperativechemotherapyforresectablecolorectallungmetastasisasystematicreviewandmetaanalysis |